This page gives some excerpts and links for current medical treatments available for dementia.
Many medical conditions can create dementia symptoms. Research focus is mainly on Alzheimer’s Disease, the commonest form of dementia. There is no cure even for Alzheimer’s Disease.
Till May 2021, there was no approved disease-modifying medicine for Alzheimer’s Disease, and available drugs were symptomatic, focused on symptoms relief. A disease modifying drug targets the underlying pathophysiology of a disease to get a more enduring clinical benefit. Symptomatic drugs aim to relieve symptoms but do not target the underlying pathophysiology of the disease.
In June 2021, FDA (Federal Drug Agency of USA) used an Accelerated Approval pathway to approve Aduhelm (aducanumab) (from BioGen) to treat patients with Alzheimer’s disease, the first novel therapy approved for Alzheimer’s disease since 2003. This pathway requires the company to verify clinical benefit in a post-approval trial (to be completed by 2030). If the sponsor cannot verify clinical benefit, the FDA may withdraw approval of the drug. Aduhelm is directed at reducing amyloid beta plaques in the brain. These plaques are a hallmark finding in the brain of patients with Alzheimer’s, and FDA expects that this reduction in the surrogate will lead to a reduction in the clinical decline.
Aduhelm is expected to be of benefit in the MCI/ early stages of AD. It has not been tested for patients in later stages of AD. While the approval is seen as a landmark that opens the way to more research and brings hope, the drug poses challenges and there has been controversy around the data from the studies and its effectiveness etc. Whereas some see it as a sign of hope and the Alzheimer’s Association has lobbied for it, some experts are skeptical and opposing the approval which they feel ignores the scientific evidence. [1,2,3,4,5,6,7]
The drug is yet to be approved or made available in India . It is also extremely expensive (several lakhs of rupees a year) and requires careful evaluation for being prescribed along with good follow-up to titrate the dose up to more effective dose levels and to watch out for side-effects.
Other than Aduhelm, there is no disease-modifying medicines for dementia, and Aduhelm is not yet approved in India, so there is no disease-modifying medicine in India.
For further reference, the 2022 Facts and Figures report of Alzheimer’s Association, USA mentions six drugs approved for use in the USA. As the excerpts with explanations below show (confirmed March 2022), the only drug that may alter the biology of the disease is aducanumab which has limited applicability and is anyway unavailable in India :
Five of these drugs — donepezil, rivastigmine, galantamine, memantine and memantine combined with donepezil — temporarily treat Alzheimer’s symptoms but do not change the underlying brain changes of Alzheimer’s or alter the course of the disease….
The sixth drug, aducanumab, was approved by the FDA in June 2021 and is the first FDA-approved drug to address the underlying biology of Alzheimer’s disease rather than the symptoms. It does this by reducing beta-amyloid plaques in the brain. It is not a cure for Alzheimer’s disease and is not appropriate for all individuals living with Alzheimer’s disease.
The National Institute on Aging has a page discussing treatment that explains that the medical approach still has a long way to go. While this page discusses Aducanumab (Aduhelm), some sections of the page (reconfirmed March 2022) remain relevant in India where this new drug is not available:
Alzheimer’s disease is complex, and it is therefore unlikely that any one drug or other intervention will ever successfully treat it in all people living with the disease…..
Most medicines work best for people in the early or middle stages of Alzheimer’s. However, it is important to understand that none of the medications available at this time will cure Alzheimer’s.
Links to some standard, authoritative sources are provided in the reference section below for further reading.
Note that some private clinics and organizations push their “stem cell therapy” product as a sure way to cure Alzheimer’s and other dementia. This is misleading. The Indian Govt. has issued guidelines on stem cell research. It has also cautioned against untested techniques and the harms to patients by laboratory manipulation of stem cells. The Indian Medical Association considers using bone marrow and cord blood stem cells for anything other than therapy for blood disorders as malpractice. Also, while stem cell research is an important direction of research for Alzheimer’s Disease, there is no approved treatment yet. The position of the Alzheimer’s Society on Stem Cell Research/ Therapies is available online 
A related topic is the effectiveness of alternate therapies. Many media reports claim that some activities or some herbs or foods can prevent or cure dementia. Various claims and reports are discussed on our page here, which also talks about how to interpret studies and evaluate alternate therapies.
References from above discussion
- Approval of Aduhelm by FDA FDA’s Decision to Approve New Treatment for Alzheimer’s Disease Opens in new window.
- FDA page with information on Aduhelm Aducanumab (marketed as Aduhelm) InformationOpens in new window.
- FDA letter regarding accelerated approval of Aduhelm Letter Ref BLA 761178 on BLA ACCELERATED APPROVAL to Biogen Inc. (marketed as Aduhelm) InformationOpens in new window.
- Alzheimer’s Disease Internal announcement on Aducunumab approval FDA approves Biogen’s aducanumabOpens in new window.
- Alzheimer’s Association, US’s page on Aducunumab approval Aducanumab Approved for Treatment of Alzheimer’s Disease Opens in new window.
- Interview of CEO of Alzheimer’s Association: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision Opens in new window.
- Article in Slate.com (Medical Examiner) Why the Approval of That Alzheimer’s Drug Is So Disturbing Opens in new window.
- Alzheimer’s Association, USA (annual report, 2022) 2022 Alzheimer’s Disease Facts and Figures report (PDF file can be downloaded from this page). Opens in new window.
-  National Institute on Aging (USA) web page on treatment How Is Alzheimer’s Disease Treated? Opens in new window.
-  Summary of guidelines: Indian national guidelines for stem cell research (2017): SummaryOpens in new window
-  The Hindu: Newspaper report explaining the position of the Indian Govt.Opens in new window
-  The Times of India: Newspaper report explaining the position of the Indian Medical Association.Opens in new window
-  Web page giving the position of Alzheimer’s Society, UK, on Stem Cell Research/ TherapiesAlzheimer’s Society’s view on stem cell research Opens in new window.
- : Web page on this site (Dementia Care Notes) discussing risk reduction research: Dementia research.
Additional links to understand the status of treatments and research:
- Alz.org page on treatments Opens in new window.
- Alz.org page on clinical trials Opens in new window.
- Alz.org overview of research Opens in new window.
- NIA page on treatment Opens in new window.
This topic read page is referred to from: Diagnosis, Treatment, Prevention
[The information on this page is a collation from standard, authoritative sources, provided only for convenience. Caregivers can check out these and other sources to get better informed about this topic.]